花旗上调礼来目标价至1500美元。分析师表示,随着美国医保(Medicare)对肥胖症治疗敞开大门,礼来口服GLP-1新药Orforglipron的上市进程和市场渗透速度将经历远超市场预期的“暴力”拉升。据追风交易台消息,花旗在11月12日的报告中表示,在与礼来CEO Dave Ricks进行路演交流后,对公司口服GLP-1药物Orforglipron的前景变得“越来越乐观”。这款药物将为礼来的...
Source Link花旗上调礼来目标价至1500美元。分析师表示,随着美国医保(Medicare)对肥胖症治疗敞开大门,礼来口服GLP-1新药Orforglipron的上市进程和市场渗透速度将经历远超市场预期的“暴力”拉升。据追风交易台消息,花旗在11月12日的报告中表示,在与礼来CEO Dave Ricks进行路演交流后,对公司口服GLP-1药物Orforglipron的前景变得“越来越乐观”。这款药物将为礼来的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.